Surreal illustration of a foot turning into tree roots, symbolizing the risks of SGLT2 inhibitors.

Diabetes Meds and Limb Loss: What You Need to Know About SGLT2 Inhibitors

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 3 min read.

"A new study highlights the increased risk of lower limb amputation associated with SGLT2 inhibitors. Understand the risks and make informed health decisions."


For individuals managing type 2 diabetes, maintaining stable blood sugar levels often involves medication. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have become increasingly popular for their effectiveness in controlling blood sugar. However, a recent study published in The BMJ raises concerns about a potential serious side effect: an increased risk of lower limb amputation.

This article delves into the findings of this important study, explains what SGLT2 inhibitors are and how they work, and provides essential information for anyone taking or considering these medications. We aim to provide a clear, accessible overview to help you make informed decisions about your health.

The findings are particularly relevant to a broad audience, especially those either managing diabetes themselves or supporting loved ones through it. The insights are geared to provide a more consumer-friendly overview of research and its implications.

AI Search Multiple angles on this topic

Diabetes and Limb Loss Statistics

Diabetes remains a major global health concern, with millions affected worldwide. Diabetic complications, including peripheral artery disease and neuropathy, can lead to lower limb amputations. While exact figures vary by region and study, the burden of diabetes-related limb loss is significant and growing. Understanding the role of medications in mitigating or contributing to this risk is crucial for patient care.

Standard Diabetes Management

Current standard approaches for type 2 diabetes include lifestyle modifications, oral hypoglycemics, and insulin therapy. SGLT2 inhibitors have emerged as a newer class of medications that target renal glucose reabsorption. However, like all therapies, they carry potential risks and benefits that must be weighed individually. Limitations include variable efficacy, side effects, and the need for ongoing monitoring.

Historical Development of SGLT2 Inhibitors

SGLT2 inhibitors work by blocking renal glucose reabsorption, increasing glucose excretion in urine. The precursor compound phlorizin was discovered in 1835, eventually leading to modern drugs like canagliflozin, dapagliflozin, and empagliflozin. The first SGLT2 inhibitor was approved by the US FDA in 2013, and subsequent approvals occurred between 2012 and 2015. These medications have since become a mainstay in type 2 diabetes treatment.

What are SGLT2 Inhibitors and How Do They Work?

Surreal illustration of a foot turning into tree roots, symbolizing the risks of SGLT2 inhibitors.

SGLT2 inhibitors are a class of prescription medicines used to lower blood sugar in adults with type 2 diabetes. They work by preventing the kidneys from reabsorbing glucose back into the blood. Instead, the excess glucose is excreted in the urine, which helps to lower overall blood sugar levels.

Commonly prescribed SGLT2 inhibitors include:

  • Canagliflozin (Invokana)
  • Dapagliflozin (Farxiga)
  • Empagliflozin (Jardiance)
  • Ertugliflozin (Steglatro)
AI Search Multiple angles on this topic

Recent Evidence on SGLT2 Inhibitors

A 2025 critical review highlights SGLT2 inhibitors' safety and their role in managing diabetes alongside cardiovascular and kidney diseases. Narrative reviews position SGLT2 inhibitors as a potential standard of care for newly diagnosed type 2 diabetes, supported by current guidelines. Next-generation SGLT2 inhibitors are being developed with improved structural and pharmacokinetic properties. A systematic integrative review of studies from 2020-2025 confirms their effectiveness in improving glycemic control, reducing cardiovascular events, and preserving renal function.

Risks and Paradigm Shifts

Healthcare providers must carefully assess patients before prescribing SGLT2 inhibitors and monitor for adverse effects, as outlined in a risks versus benefits review. Recent cardiovascular outcome trials have demonstrated significant mortality benefits, leading to a paradigm shift in treating patients with heart disease and diabetes. Beyond glycemic control, SGLT2 inhibitors now show cardiovascular and renal protective effects, reshaping their clinical role.

Comparative Effectiveness

When compared to other diabetes medications, SGLT2 inhibitors offer unique benefits such as weight loss and blood pressure reduction. However, head-to-head trials are limited, and comparative effectiveness may vary by patient population. The choice of therapy often depends on individual comorbidities, cost, and prescribing patterns. More research is needed to directly compare SGLT2 inhibitors with newer drug classes like GLP-1 receptor agonists.

These medications are often prescribed alongside diet and exercise to improve blood sugar control in people with type 2 diabetes. While effective, it’s important to be aware of the potential risks associated with their use.

Making Informed Decisions About Your Diabetes Treatment

If you are currently taking an SGLT2 inhibitor, it is crucial to have an open and honest conversation with your doctor. Discuss the potential risks and benefits of continuing the medication, and explore alternative treatment options if necessary. Don't stop taking any medication without consulting your healthcare provider first. Regular foot exams and proactive management of any foot issues are also vital for those taking SGLT2 inhibitors.

AI Search Multiple angles on this topic

Expert Synthesis

Experts agree that SGLT2 inhibitors represent a significant advancement in diabetes management, offering benefits beyond glucose lowering. However, their adoption is not universal, and real-world underuse persists. Ongoing education and guideline dissemination are critical to optimizing their use. The balance of risks and benefits must be tailored to each patient's clinical profile.

Market Growth and Future Directions

The global SGLT2 inhibitors market was valued at USD 17.8 billion in 2025 and is projected to grow to USD 34.5 billion by 2036, with a CAGR of 6.2%. Future Market Insights estimates demand will increase to USD 18.9 billion in 2026. Market expansion is driven by rising diabetes prevalence and expanding indications beyond type 2 diabetes, including cardiovascular and kidney diseases. Ongoing innovation aims to develop next-generation compounds with improved efficacy and safety profiles.

Pleiotropic Effects and Metabolic Modulation

SGLT2 inhibitors have demonstrated extensive pleiotropic effects in treating type 2 diabetes and its complications, moving beyond mere glycemic control to multitarget metabolic regulation. Their unique mechanisms allow them to influence various metabolic pathways, offering potential benefits for multiple organ systems. This broader impact positions them as disease-modifying therapies rather than simple glucose-lowering agents. However, realizing this potential requires addressing systemic challenges in healthcare delivery and access.

Real-World Evidence and Patient Outcomes

Real-world studies highlight underuse of SGLT2 inhibitors among eligible patients with type 2 diabetes, despite proven benefits. Research across diverse patient populations confirms their effectiveness in reducing liver fat and improving renal outcomes. Data from clinical practice settings show that SGLT2 inhibitors can slow chronic kidney disease progression and reduce end-stage kidney disease risk. Comparative real-world evidence suggests GLP-1 receptor agonist/SGLT2 inhibitor combination therapies may offer additional benefits in certain populations.

Amputation reports across ertugliflozin trial groups

  • 0.1%Across seven trials, reported non-traumatic lower-limb amputations were 0.1% in the comparator group, compared with 0.2% for ertugliflozin 5 mg and 0.5% for ertugliflozin 15 mg.[1]

What the amputation evidence does-and does not-establish

The pooled estimate does not establish that SGLT-2 inhibitors raise amputation risk: its confidence interval includes no difference, and the analysis reports substantial variation across trials. That leaves a possible increase unresolved rather than confirming a class-wide effect.[2]

The proposed explanation involving reduced fluid volume and poorer blood flow to the lower extremities is a hypothesis, not a demonstrated pathway. The cited discussion links that possibility to observed weight and blood-pressure reductions, but the mechanism remains unclear.[3] [4]

How trial comparisons and patient factors shape the picture

The CANVAS Program combined two randomized trials of canagliflozin versus placebo in 10,142 people with type 2 diabetes and high cardiovascular risk; mean follow-up was 188.2 weeks. This describes a particular drug, population, and observation period, so it does not by itself settle risk across all SGLT2 inhibitors.[5]

A systematic review described an elevated-risk signal but also substantial uncertainty, with estimates potentially varying according to patients’ baseline characteristics and the comparator drug. That makes comparisons between different medicines and populations important to interpretation.[6]

Reports identify leg and foot infections, gangrene, and diabetic foot ulcers as common events preceding amputation. People who had amputations were also more likely to have several baseline characteristics, including peripheral arterial disease or a prior amputation; these patterns describe risk context, not proof that a medicine caused an individual event.[1]

What remains unresolved about limb risk

  • Does early SGLT2-inhibitor use change outcomes in people with diabetic foot conditions? The cited review says longitudinal and prospective evidence without confounding is lacking, so the effect in that setting remains unsettled.[7]
  • Which patient characteristics meaningfully alter the balance of limb risk? The sources point to baseline differences and risk factors, but say the issue has not been resolved definitively.[4] [6]

Short answers on limb complications

What does preventative foot care guidance emphasize?

The FDA guidance cited here emphasizes monitoring for new pain, tenderness, sores, ulcers, and infections in the legs and feet, while considering amputation risk factors when selecting diabetes medicines.[8]

Sources

  1. label (www.accessdata.fda.gov)
  2. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals. (pubmed.ncbi.nlm.nih.gov)
  3. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (pmc.ncbi.nlm.nih.gov)
  4. SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis (pmc.ncbi.nlm.nih.gov)
  5. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. (pubmed.ncbi.nlm.nih.gov)
  6. Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies (pmc.ncbi.nlm.nih.gov)
  7. The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review (pmc.ncbi.nlm.nih.gov)
  8. FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) | FDA (www.fda.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are SGLT2 inhibitors, and how do they affect blood sugar levels in people with type 2 diabetes?

SGLT2 inhibitors are prescription medicines designed to lower blood sugar in adults diagnosed with type 2 diabetes. They function by inhibiting the kidneys from reabsorbing glucose back into the bloodstream. Instead, the excess glucose is eliminated through urine, which helps in reducing overall blood sugar levels. Common examples of SGLT2 inhibitors include Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), and Ertugliflozin (Steglatro).

2

What specific risks are associated with SGLT2 inhibitors, particularly concerning lower limb amputation?

Recent research, such as that published in *The BMJ*, has highlighted a potential association between the use of SGLT2 inhibitors and an increased risk of lower limb amputation. While SGLT2 inhibitors like Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), and Ertugliflozin (Steglatro) are effective at controlling blood sugar, it is vital to understand and discuss these potential risks with your healthcare provider. The study indicates a statistically significant correlation, although further research is needed to fully understand the underlying mechanisms contributing to this increased risk.

3

If I am taking an SGLT2 inhibitor, what steps should I take to protect my health and manage potential risks?

If you are currently prescribed an SGLT2 inhibitor such as Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), or Ertugliflozin (Steglatro), it is important to maintain open communication with your doctor. Discuss both the benefits and potential risks associated with the medication, and explore alternative treatments if necessary. Do not discontinue any medication without professional medical advice. Regular foot examinations and proactive management of any foot-related issues are also crucial.

4

Beyond blood sugar control, are there other health implications or side effects linked to SGLT2 inhibitors that I should be aware of?

Besides the risk of lower limb amputation, SGLT2 inhibitors like Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), and Ertugliflozin (Steglatro) can have other side effects. Some patients may experience urinary tract infections or yeast infections due to the increased glucose in the urine. Additionally, there is a risk of dehydration and ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones. It's important to discuss all potential side effects and health implications with your doctor to make an informed decision.

5

What alternatives to SGLT2 inhibitors are available for managing type 2 diabetes, and how do they compare in terms of effectiveness and risks?

There are several alternatives to SGLT2 inhibitors such as Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), and Ertugliflozin (Steglatro) for managing type 2 diabetes. These include Metformin, Sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and insulin. Metformin is often the first-line treatment due to its effectiveness and safety profile. Sulfonylureas can effectively lower blood sugar but may carry a higher risk of hypoglycemia. DPP-4 inhibitors are generally well-tolerated but might not be as potent as other options. GLP-1 receptor agonists offer the benefit of weight loss but are administered via injection. Insulin is highly effective but requires careful monitoring to avoid hypoglycemia. The choice of medication should be personalized based on individual health profiles and in consultation with a healthcare provider.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.